share_log

Raymond James Maintains Outperform on Xilio Therapeutics, Lowers Price Target to $13

Benzinga Real-time News ·  Nov 10, 2022 04:22

Raymond James analyst Dane Leone maintains Xilio Therapeutics (NASDAQ:XLO) with a Outperform and lowers the price target from $31 to $13.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment